These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 15734832)

  • 1. A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome.
    Summers SA; Nelson DH
    Diabetes; 2005 Mar; 54(3):591-602. PubMed ID: 15734832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Syndrome in Cushing's Syndrome Patients.
    Ferraù F; Korbonits M
    Front Horm Res; 2018; 49():85-103. PubMed ID: 29894989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceramides - Lipotoxic Inducers of Metabolic Disorders.
    Chaurasia B; Summers SA
    Trends Endocrinol Metab; 2015 Oct; 26(10):538-550. PubMed ID: 26412155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The equine metabolic syndrome peripheral Cushing's syndrome.
    Johnson PJ
    Vet Clin North Am Equine Pract; 2002 Aug; 18(2):271-93. PubMed ID: 15635908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adrenal steroids and the metabolic syndrome.
    Thomson SP; Stump CS; Kurukulasuriya LR; Sowers JR
    Curr Hypertens Rep; 2007 Dec; 9(6):512-9. PubMed ID: 18367016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The coming of age of the metabolic syndrome.
    Alexander CM
    Diabetes Care; 2003 Nov; 26(11):3180-1. PubMed ID: 14578259
    [No Abstract]   [Full Text] [Related]  

  • 7. Pathophysiology of diabetes mellitus in Cushing's syndrome.
    Pivonello R; De Leo M; Vitale P; Cozzolino A; Simeoli C; De Martino MC; Lombardi G; Colao A
    Neuroendocrinology; 2010; 92 Suppl 1():77-81. PubMed ID: 20829623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Ceramides in Diabetes and Cardiovascular Disease Regulation of Ceramides by Adipokines.
    Field BC; Gordillo R; Scherer PE
    Front Endocrinol (Lausanne); 2020; 11():569250. PubMed ID: 33133017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies.
    Rizvi AA; Stoian AP; Rizzo M
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting ceramide metabolism in obesity.
    Aburasayn H; Al Batran R; Ussher JR
    Am J Physiol Endocrinol Metab; 2016 Aug; 311(2):E423-35. PubMed ID: 27382035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance.
    Holland WL; Brozinick JT; Wang LP; Hawkins ED; Sargent KM; Liu Y; Narra K; Hoehn KL; Knotts TA; Siesky A; Nelson DH; Karathanasis SK; Fontenot GK; Birnbaum MJ; Summers SA
    Cell Metab; 2007 Mar; 5(3):167-79. PubMed ID: 17339025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceramides in Metabolism: Key Lipotoxic Players.
    Chaurasia B; Summers SA
    Annu Rev Physiol; 2021 Feb; 83():303-330. PubMed ID: 33158378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceramides in insulin resistance and lipotoxicity.
    Summers SA
    Prog Lipid Res; 2006 Jan; 45(1):42-72. PubMed ID: 16445986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications.
    Isidori AM; Graziadio C; Paragliola RM; Cozzolino A; Ambrogio AG; Colao A; Corsello SM; Pivonello R;
    J Hypertens; 2015 Jan; 33(1):44-60. PubMed ID: 25415766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingolipid Metabolism: New Insight into Ceramide-Induced Lipotoxicity in Muscle Cells.
    Bandet CL; Tan-Chen S; Bourron O; Le Stunff H; Hajduch E
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30678043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting sphingolipid metabolism in the treatment of obesity/type 2 diabetes.
    Bellini L; Campana M; Mahfouz R; Carlier A; Véret J; Magnan C; Hajduch E; Le Stunff H
    Expert Opin Ther Targets; 2015; 19(8):1037-50. PubMed ID: 25814122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zinc alpha-2 glycoprotein is overproduced in Cushing's syndrome.
    Escoté X; Aranda GB; Mora M; Casals G; Enseñat J; Vidal O; Esteban Y; Halperin I; Hanzu FA
    Endocrinol Diabetes Nutr; 2017 Jan; 64(1):26-33. PubMed ID: 28440767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Ceramide in Apoptosis and Development of Insulin Resistance.
    Kuzmenko DI; Klimentyeva TK
    Biochemistry (Mosc); 2016 Sep; 81(9):913-27. PubMed ID: 27682164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiology of dyslipidemia in Cushing's syndrome.
    Arnaldi G; Scandali VM; Trementino L; Cardinaletti M; Appolloni G; Boscaro M
    Neuroendocrinology; 2010; 92 Suppl 1():86-90. PubMed ID: 20829625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cushing's syndrome.
    Shibli-Rahhal A; Van Beek M; Schlechte JA
    Clin Dermatol; 2006; 24(4):260-5. PubMed ID: 16828407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.